Surface Oncology Announces ISS and Glass Lewis Both Recommend Stockholders Vote “FOR” the Proposed Merger with Coherus BioSciences
31 août 2023 16h01 HE
|
Surface Oncology, Inc.
CAMBRIDGE, Mass., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Surface Oncology, Inc. (Nasdaq: SURF) (“Surface”), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target...
Surface Oncology Reports Financial Results and Corporate Highlights for Second Quarter 2023
02 août 2023 07h00 HE
|
Surface Oncology, Inc.
CAMBRIDGE, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...
Coherus to Acquire Surface Oncology
16 juin 2023 07h01 HE
|
Surface Oncology, Inc.
– Surface acquisition and potential toripalimab approval will transform Coherus into an I-O company with multiple next-generation immunotherapies in clinical development funded by growing revenues – ...
Surface Oncology Reports Financial Results and Corporate Highlights for First Quarter 2023
04 mai 2023 07h00 HE
|
Surface Oncology, Inc.
Updated clinical data from Phase 2 studies evaluating SRF388 in both liver and lung cancer expected in the second quarter of 2023 Projected cash runway guidance remains unchanged with funding...
Surface Oncology Presents New Preclinical Data on SRF114, a fully human anti-CCR8 antibody, at the AACR Annual Meeting 2023
18 avr. 2023 07h00 HE
|
Surface Oncology, Inc.
CAMBRIDGE, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...
Surface Oncology to Present New Preclinical SRF114 Data at the American Association for Cancer Research (AACR) Annual Meeting 2023
16 mars 2023 08h00 HE
|
Surface Oncology, Inc.
CAMBRIDGE, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...
Surface Oncology Reports Financial Results and Corporate Highlights for Fourth Quarter and Full Year 2022
09 mars 2023 07h00 HE
|
Surface Oncology, Inc.
SRF388 clinical program advancing well; updated clinical data expected in the first half of 2023 First patient dosed in a Phase 1/2 study evaluating SRF114, a potential best-in-class anti-CCR8...
Surface Oncology to Participate in the Cowen 43rd Annual Health Care Conference
28 févr. 2023 16h15 HE
|
Surface Oncology, Inc.
CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...
Surface Oncology to Participate in the 2023 Guggenheim Oncology Days Conference
02 févr. 2023 08h00 HE
|
Surface Oncology, Inc.
CAMBRIDGE, Mass., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...
Surface Oncology Announces First Patient Dosed in a Phase 1/2 Study Evaluating SRF114, a Potential Best-In-Class Anti-CCR8 Antibody, in Patients with Advanced Solid Tumors
05 janv. 2023 07h30 HE
|
Surface Oncology, Inc.
SRF114 is designed to preferentially deplete CCR8+ Treg cells within the tumor microenvironment and has demonstrated highly specific CCR8-exclusive binding and reduced tumor growth in pre-clinical...